The latest update is out from Bonus Biogroup ( (IL:BONS) ).
Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID-19 patients. This approval allows the company to test the drug’s safety and efficacy in the U.S., potentially reducing mortality rates and improving recovery times in ARDS patients, with previous trials showing promising results.
More about Bonus Biogroup
Bonus Biogroup operates in the biotechnology industry, focusing on developing innovative medical treatments. The company is involved in the research and development of drugs aimed at addressing critical health conditions, with a particular emphasis on respiratory diseases.
YTD Price Performance: 150.0%
Average Trading Volume: 9,158
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $61.91M
See more data about BONS stock on TipRanks’ Stock Analysis page.